title: Left ventricular function in pulmonary hypertension.
abstract: To elucidate left ventricular function in pulmonary hypertension, we measured parameters of left ventricular as well as right ventricular function by echocardiography in 11 patients with pulmonary hypertension (idiopathic pulmonary artery hypertension in 4, chronic thromboembolic pulmonary hypertension in 5, and other pulmonary hypertension in 2). The percent change in these parameters 6 months after treatment with pulmonary artery vasodilators (beraprost in 8 and sildenafil in 3) was assessed. There was a correlation between the relative change in right ventricular systolic pressure (RVSP) and the relative changes in left ventricular outflow tract velocity-time integral (r = -0.730, P = 0.011) and mitral valve velocity-time integral (r = -0.621, P = 0.041). However, there was no correlation between the relative change in RVSP and the relative changes in left ventricular ejection fraction, left ventricular diastolic dimension, and systolic blood pressure. The relative change in RVSP was also correlated with the relative change in early diastolic myocardial velocity at the medial mitral annulus (r = -0.675, P = 0.023). Reduction of RVSP by pulmonary artery vasodilators might increase left ventricular preload, leading to an increase in stroke volume. Right ventricular load reduction might improve left ventricular diastolic function in patients with pulmonary hypertension, possibly through altered interventricular septal performance.
authors.affiliation: Department of Cardiovascular Medicine, Dokkyo Medical University, 880 Kitakobayashi, Mibu, 321-0293, Tochigi, Japan.
authors.forename: Hirohisa
authors.initials: H
authors.lastname: Amano
authors.forename: Shigeru
authors.initials: S
authors.lastname: Toyoda
authors.forename: Takuo
authors.initials: T
authors.lastname: Arikawa
authors.forename: Shu
authors.initials: S
authors.lastname: Inami
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Otani
authors.forename: Yu
authors.initials: Y
authors.lastname: Nishi
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Kitagawa
authors.forename: Isao
authors.initials: I
authors.lastname: Taguchi
authors.forename: Shichiro
authors.initials: S
authors.lastname: Abe
authors.forename: Teruo
authors.initials: T
authors.lastname: Inoue
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure; D003971:Diastole; D015150:Echocardiography, Doppler; D011464:Epoprostenol / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology*; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D008943:Mitral Valve / Q000503:physiopathology; D010879:Piperazines / Q000627:therapeutic use; D011687:Purines / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D013318:Stroke Volume; D013450:Sulfones / Q000627:therapeutic use; D013599:Systole; D013997:Time Factors; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology*; D018497:Ventricular Dysfunction, Right / Q000503:physiopathology; D016277:Ventricular Function, Left / Q000187:drug effects; D016278:Ventricular Function, Right; D017725:Ventricular Pressure
chemical_list: D000959:Antihypertensive Agents; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; C048081:beraprost; D000068677:Sildenafil Citrate; D011464:Epoprostenol